: Speaker List

Speaker View

Below is a listing of all sessions the speaker is scheduled to present.

Jaspreet Sidhu

VP, Business Development and Pharmaceutical Microbiology

Molecular Epidemiology, Inc. (MEI)

Speaker Bio

Current Position: VP Business Development and Pharmaceutical Microbiology, Molecular Epidemiology, Inc. Lake Forest Park, WA

Principal Scientist/Laboratory Research Director, University of Washington, Seattle, WA, Aug 2001-Dec 2004

Senior Research Scientist, University of Washington, Seattle, WA, 1996-2001

Visiting Scientist, University of Washington, Seattle, WA, 1993-1996

Post-Doctoral Fellow, University of Washington, Seattle WA, 1990-1993

Education, Certifications and Interests

PhD, Biochemistry, 1989, Brunel University and Max-Planck Institute for Biophysical Chemistry, Goettingen, Germany
BS (Honors), Applied Biochemistry, 1985, Brunel, University of West London, UK

Professional Memberships

Have a Question?

You can pose a question to the speaker by clicking on the "Suggest a Question" icon at the end of the session title. Appropriate questions will be answered during the session as time permits (not all questions will be answered).
Wednesday, March 30, 2011
Conference Program
Suggest A Question for this Session
Microbial Controls in Biopharmaceutical Manufacturing
Room: 1E13 ~ 2:00 pm - 3:30 pm (Wednesday, March 30, 2011)
Despite frequent and intensive microbial monitoring and disinfection
procedures, the industry has continued to experience ongoing incidents of contamination of facilities and equipment. This paper and study evaluates and better explains typical failure modes for ineffective microbial contamination prevention and treatment. Most failures to resolve process and facility contamination can be attributed to shortcomings in conventional microbial monitoring and speciation methods (diagnostics), combined with resulting shortcomings in conventional liquid disinfection (misdirected or sub-lethal decontamination treatment). This study demonstrates how new diagnostic and analytical technologies when used in conjunction with classical microbiological approaches can better pinpoint the root cause and mechanisms of the microbial contamination and in turn, enable a targeted, more effective decontamination treatment rather than a scattered "shotgun" approach.
Accurate and comprehensive knowledge of the entire process flow relative to the recovered EM isolates is part of a thorough microbial control program. The goal is to have accurate and precise data demonstrating where incursion points exist, and control those points to limit or prevent migration into the process flow. Historic identification of clean room EM isolates has been limited to the genus or group-level for most organisms, with some ability to provide species level identification only if needed. Today, many rapid technologies including DNA-based methods are available which can provide a far deeper identification level of microorganisms. This may appear to be an invaluable tool for performing general investigations and trending, and an essential part of any investigation into aseptic excursions and the risk-based analysis required to address those issues. If used appropriately, these technologies can certainly direct management decisions in a more cost-effective manner).

However, this increase in technology also comes with an increase in possible identifications and with the likelihood of identifying a far greater number of "objectionable" environmental organisms (e.g. coliforms, potential pathogens) than ever before including organisms in environments not addressed by conventional application of standard disinfectants. With the enhancement in this technology, the industry and regulators should be prepared with improved procedures to address these findings with rational, manageable approaches and with the ability to determine whether these are 1) correct and accurate Identifications, 2) have meaning as an “objectionable” organism, and 3) develop demonstrated effective solutions for control and remediation. The paper suggests a new, higher standard for monitoring, control and prevention as well as for the best scientifically robust corrective response to a potential objectionable contamination event.
Jaspreet Sidhu, PhD - VP, Business Development and Pharmaceutical Microbiology, Molecular Epidemiology, Inc. (MEI)
Steve Weitzel - Vice President Technical Operations, CANI
Reed Exhibitions
  • Pharmaceuticals
  • Biologics
  • Generics
  • Contract Services
ConferencePath System © 2004 - 2015 ConferencePath & MasseyMedia. All Rights Reserved.